RxDoctor Payments Data

Jawad Ilyas, MD

Gastroenterology · Gainesville, GANPI 1629276159

Payments from drug & device makers

What this record shows

This record is dominated by speaking fees: $30,841 of the $40,117 with a category attached, or 76.9%. 41 manufacturers reported payments, led by AbbVie at 58.5% of the total. Among gastroenterology clinicians in GA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$40,117in general payments, 2019–2025

Across 386 payments — averaging $103.93 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$23K
  • Madrigal Pharmaceuticals$12K
  • Takeda Pharmaceuticals U.S.A., Inc.$538
  • Salix Pharmaceuticals, A Division Of Bausch Health US, LLC$507
  • Gilead$336
  • Pfizer$302
  • plus $3K from 35 others

What the payments were for

  • Speaking & faculty fees$30,84177%
  • Travel & lodging$1,3833%
  • Food & beverage$7,82319%
  • Education$700%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$40,117 in reported general payments places this provider in the 95th percentile of 492 gastroenterology providers in Georgia.

See all gastroenterology providers in Georgia

Medicare billing

Part B allowed, 2024
$228,692
Medicare patients
368
Services billed
7,601

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
XifaxanRifaximin84$302,378
RinvoqUpadacitinib13$101,423
CreonLipase/Protease/Amylase32$100,208
LinzessLinaclotide31$22,926
MounjaroTirzepatide14$21,514
Ursodiol39$8,224
Mesalamine25$7,473
SutabSod Sulf/Pot Chloride/Mag Sulf40$6,360
Sod Sulf-Potass Sulf-Mag SulfSodium, Potassium,mag Sulfates87$6,196
Azathioprine12$5,523
Budesonide DrBudesonide19$2,689
Sucralfate42$2,063
CholestyramineCholestyramine (With Sugar)32$1,940
Pantoprazole Sodium137$1,737
Omeprazole121$1,616

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Salix Pharmaceuticals, A Division Of Bausch Health US, LLCXifaxan$507$302,37884 claims
AbbVieRinvoq, Creon, Linzess$23,471$224,55776 claims
Lilly USA, LLCMounjaro$216$21,51414 claims
Braintree Laboratories, Inc.Sutab$51$6,36040 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 95th percentile of 492 gastroenterology providers in Georgia.

Other gastroenterology in Gainesville

See the full list for Georgia

Where these figures come from

Is this you, or does something look wrong? →